stockrowPharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.
- Revenue
- +20.9%
- EPS
- +190.9%
- Free cash flow
- +0.42%
- Total debt
- +1.61%
Quarter to September 2026, against a year earlier
Follow PHAR
Alert me
Pharming Group N.V. Sponsored ADR (PHAR) EV/Sales
As of 6 November 2026, Pharming Group N.V. Sponsored ADR (PHAR) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from −5.2× (September 2023) to 52.0× (December 2020); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.0× | 51.89% |
| FY2024 | 2.0× | (28.37%) |
| FY2023 | 2.8× | (15.75%) |
| FY2022 | 3.3× | (88.74%) |
| FY2021 | 29.3× | (34.68%) |
| FY2020 | 44.8× | (13.89%) |
| FY2019 | 52.0× | 0.00% |
| FY2018 | 52.0× | 0.00% |
| FY2017 | 52.0× | 0.00% |
| FY2016 | 52.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.6× | (15.10%) |
| Jun 2026 | 1.9× | (41.22%) |
| Mar 2026 | 3.2× | 4.65% |
| Dec 2025 | 3.0× | 18.85% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LTGO Latigo Biotherapeutics Inc compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | 1.5× |
| PHAR Pharming Group N.V. Sponsored ADR | 2.0× |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.3× |
| GLUE Monte Rosa Therapeutics, Inc. compare | 7.0× |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)